[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN113943374A - Polypeptide compound of interleukin 15 and receptor thereof - Google Patents

Polypeptide compound of interleukin 15 and receptor thereof Download PDF

Info

Publication number
CN113943374A
CN113943374A CN202111123534.XA CN202111123534A CN113943374A CN 113943374 A CN113943374 A CN 113943374A CN 202111123534 A CN202111123534 A CN 202111123534A CN 113943374 A CN113943374 A CN 113943374A
Authority
CN
China
Prior art keywords
ser
thr
val
gly
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202111123534.XA
Other languages
Chinese (zh)
Other versions
CN113943374B (en
Inventor
芦迪
霍永庭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Fapon Biopharma Inc
Original Assignee
Guangdong Fapon Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Fapon Biopharma Inc filed Critical Guangdong Fapon Biopharma Inc
Priority to CN202111123534.XA priority Critical patent/CN113943374B/en
Publication of CN113943374A publication Critical patent/CN113943374A/en
Priority to TW111136248A priority patent/TW202321315A/en
Priority to PCT/CN2022/121068 priority patent/WO2023046116A1/en
Application granted granted Critical
Publication of CN113943374B publication Critical patent/CN113943374B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to the field of biomedicine, in particular to a disulfide bond modified polypeptide compound containing interleukin 15 and a receptor thereof. And a non-natural interchain bond is formed between the IL15 and the IL15R alpha, the non-natural interchain bond is formed between a first mutant residue of IL15 and a second mutant residue of IL15R alpha, the first mutant residue of IL15 is an E mutation at the 90 th position to be C, and the second mutant residue of IL15R alpha is a P mutation at the 67 th position to be C.

Description

Polypeptide compound of interleukin 15 and receptor thereof
Technical Field
The invention relates to the field of biomedicine, in particular to a disulfide bond modified polypeptide compound containing interleukin 15 and a receptor thereof.
Background
The cell factor plays an important role in the immune regulation of human bodies, participates in the immune regulation of tumors, and is closely related to the generation and development of the tumors. In immunotherapy, cytokines can directly act on immune effector cells in the tumor microenvironment to enhance the tumor suppression effect. Through clinical studies and animal experiments, many cytokines have been demonstrated to have significant anti-tumor activity, and several cytokines have been approved by FDA for marketing.
Interleukin 15(IL-15) is a cytokine of about 12-14kD discovered by Grabstein et al in 1994, and can play a role in normal immune responses in the body, such as promoting the proliferation of T cells, B cells, and Natural Killer (NK) cells.
IL-15 belongs to members of the four Small alpha helical bundle cytokine families (Small four alpha-helix bundle family of cytokines). IL-15 needs to exert biological activity by binding to its receptor. The IL-15 receptor consists of three receptor subunits: IL-15 receptor alpha (IL-15R alpha), IL-2 receptor beta (IL-2R beta, also known as IL-15R beta or CD122), and yc (also known as CD 132). IL-15 Ra contains a Sushi domain, can bind to IL-15, and is necessary for the bound IL-15 to exert biological functions.
In recent years, IL15 and IL15 receptors have been used more frequently to construct fusion proteins, and in order to improve the stability of fusion proteins, disulfide bonds have been introduced between interleukin 15 and its receptor.
Disclosure of Invention
The invention provides an IL15/IL15R alpha polypeptide compound, wherein a non-natural interchain bond is arranged between IL15 and IL15R alpha, the non-natural interchain bond is formed between a first mutation residue of IL15 and a second mutation residue of IL15R alpha, the first mutation residue of IL15 is the mutation of E at the 90 th position into C, and the second mutation residue of IL15R alpha is the mutation of P at the 67 th position into C.
In some embodiments, the IL15R a extracellular region is full length or IL15R a sushi domain.
In some embodiments, the IL15R a has 73-175 amino acids.
In some embodiments, the IL15 has the amino acid sequence shown in SEQ ID No. 9.
In some embodiments, the IL15R a has the amino acid sequence shown in SEQ ID No.10, SEQ ID No.11, SEQ ID No.12, SEQ ID No.13 or SEQ ID No. 14.
The invention also relates to a vector containing a nucleic acid as described above.
The invention also relates to a host cell comprising a nucleic acid as described above or a vector as described above.
The invention also relates to a method for preparing the IL15/IL15R alpha polypeptide complex, which comprises the following steps:
transforming a host cell with a vector as described above;
culturing the transformed host cell; and
collecting the IL15/IL15R alpha polypeptide complex expressed in the host cell.
The present invention also relates to a pharmaceutical composition comprising an IL15/IL15R alpha polypeptide complex as described above and a pharmaceutically acceptable carrier, excipient, or stabilizer.
The invention also relates to the application of the IL15/IL15R alpha polypeptide complex in preparing medicines for treating diseases.
Drawings
FIG. 1 is a schematic representation of the interaction of IL15/IL15R α with IL2/15R β/γ C complex;
FIG. 2 is a schematic representation of the intramolecular disulfide bond mutation pairing between IL15 (ligand) and IL15R α (receptor) in the present example;
FIG. 3 is a schematic diagram of the structure of an exemplary IL15/IL15R α complex;
FIG. 4 is a schematic diagram of an exemplary specific application scenario of IL15/IL15R alpha complex;
FIG. 5 shows the result of gel electrophoresis detection of disulfide-bond modified IL15/IL15R alpha complex;
FIG. 6 is a graph showing the results of detection of binding force (@ TIGIT) of disulfide-bond engineered and unmodified IL15/IL15R α complex to the targeting region;
FIG. 7 is a detection result of binding force (@ PD-L1) of disulfide bond modified and unmodified IL15/IL15R alpha complex to a target region.
Detailed Description
Reference will now be made in detail to embodiments of the invention, one or more examples of which are described below. Each example is provided by way of explanation, not limitation, of the invention. In fact, it will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment, can be used on another embodiment to yield a still further embodiment. All documents, including publications, patents, and patent applications, cited in this specification are herein incorporated by reference in their entirety.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.
Embodiments of the present invention will be described in detail with reference to examples.
Example 1 disulfide bond engineering of the IL15/IL15R alpha Complex
Disulfide bond engineering was designed between IL15 and IL15R α to facilitate the formation of covalent disulfide bond linkages between non-covalently linked IL15 and IL15R α. The mutation sites are as follows:
combination of IL15 IL15Rα
1 E87C D96+C97
2 E90C P67C
3 E93C R35C
An exemplary scenario for selecting the IL15/IL15R alpha complex: the heavy chain variable region (VH) variable region of the target antigen is connected to IL15R alpha through a Linker and then connected with Fc of the antibody through Hinge; the light chain variable region (VL) targeting the same antigen is connected to IL15 through a Linker to prepare a targeting IL15/IL15R alpha compound.
Figure BDA0003277908210000031
Figure BDA0003277908210000041
The above complexes can be applied to molecules targeting the same antigen or target, such as the structure of fig. 4B or fig. 4C (the scfv targets the same antigen or target), and can also be used to target 2 or more antigen or target molecules, such as fig. 4A or fig. 4C (the scfv targets different antigens or targets), and the application scenario of the present complexes is not limited to the above examples.
Example 2 preparation of composite samples
Protein transient expression:
after a plasmid containing a target gene forms a cation complex with a transfection reagent PEI, the cation complex is introduced into a host cell Expi293, and a foreign gene on the plasmid is transcribed and translated in the cell during the period that the plasmid is in the cell, so that the target protein is obtained.
Expi293 was cultured at 37 ℃ in 8% carbon dioxide at 130rpm and 2E6 cells were seeded into 1L shake flasks at approximately 300ml by cell counting prior to transfection. Preparation of transfection complexes preparation for transfection: firstly, 750 mu g of target plasmid is added into a 50ml centrifuge tube containing 15ml of Opti-MEM reagent, and the mixture is gently mixed and marked as tube A; adding 1.5mg of PEI into a 50ml centrifuge tube containing 15ml of Opti-MEM reagent, mixing the reagent evenly, and incubating the reagent for 5min at room temperature, wherein the reagent is marked as a tube B; and dropwise adding the PEI diluent of the tube B into the DNA diluent of the tube A, slightly and uniformly mixing, incubating at room temperature for 15min, adding the PEI-target plasmid compound into the Expi293 cells after the incubation is finished, and placing the cells in a shaking table at 37 ℃ for continuous culture. The samples were collected until after D7-D10.
And (3) purifying a compound sample:
the transient cell expression solution was centrifuged at 9000rpm/20min, and the supernatant was collected and sterile-filtered through a 0.22 μm filter. The purification was performed by ProA affinity chromatography. The process is as follows, using an AKTA avant 150 chromatographic apparatus, with at least 5CV of equilibration buffer (10mM PBS) to equilibrate a chromatography column (e.g., MabSelectSuRe LX, GE), loading the sample onto the column, allowing the target protein to adsorb onto the column while other impurities are separated by breakthrough. After the loading was completed, the column was washed again with at least 5CV of equilibration buffer (10mM PBS), followed by elution of the target protein with elution buffer (20mM NaAc, pH 3.4), and a neutralization buffer (1M Tris, pH8.0) was added to the collection tube in advance, the volume of the neutralization buffer added being determined according to the estimated content of the eluted sample, and typically 10% of the elution volume was added.
Example 3 detection of disulfide-modified IL15/IL15R alpha Complex by gel electrophoresis
Performing SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) detection on the disulfide bond modified IL15/IL15R alpha complex, wherein the detection result is shown in figure 5, and a band exists between 25KD and 35KD of molecular weight, which indicates that a free light chain exists; compound 1 and Compound 2 (disulfide bond engineered positions IL15(E90C)/IL15R alpha (P67C)) have no band between 25KD and 35KD in molecular weight, which indicates that disulfide bond engineering is successful, and Compound 3 (disulfide bond engineered positions IL15(E87C)/IL15R alpha (D96+ C97)) and Compound 4 (disulfide bond engineered positions IL15(E93C)/IL15R alpha (R35C)) have bands between 25KD and 35KD in molecular weight, which indicates that free light chain exists and disulfide bond engineering fails.
Example 4 targeting moiety affinity assay
TIGIT end binding Activity assay
The binding activity of the double-antibody molecule (TIGIT end) and CHO-TIGIT cells is detected by an FCM experimental method. Preparation of 3% BSA buffer: weighing 4.5g of BSA into 150mL of 1XPBS, uniformly mixing, and placing on ice for later use; antibody dilution: the test antibody and positive control were diluted with 3% BSA to an initial concentration of 800nM, and the subtype control was diluted to an initial concentration of 20. mu.g/mL, at a volume of 300. mu.L, at 10 points in a 3-fold gradient dilution (100+ 200); and (3) detecting the binding activity: cells were counted and plated: counting the R0254-3 cells, and dividing the cells into 96-well V-shaped plates according to 100 mu L and 2E + 05/well; adding 50 mu L of antibody with different concentrations into cells, incubating for 0.5h at 2-8 ℃, adding 50 mu L of ligand, and incubating for 0.5h at 2-8 ℃; centrifuging at 350Xg for 5min, removing supernatant, and adding 200 μ L/well 3% BSA; centrifuging at 350Xg for 5min, removing supernatant, preparing fluorescent antibodies PE Goat anti-human IgG Fc and PE Goat anti-mouse IgG Fc (diluted at 1:500 x) by 3% BSA, adding into a corresponding 96-well plate according to 100 mu L/well, and incubating at 2-8 ℃ for 30 min; centrifuging for 5min at 350g, removing supernatant, and washing cells once with 3% BSA; centrifuging at 350Xg for 5min, removing supernatant, and adding 1XPBS for resuspending cells at 100 μ L/hole; the detection result is shown in figure 6, and the detection result is equivalent to the affinity of the molecule without disulfide bond modification (the sequence is the same as that of the compound 1 except the disulfide bond modification) according to the computer detection of the standard operation procedure of the CytoFLEX flow cytometer, which indicates that the disulfide bond modification does not influence the affinity of the targeting region.
PD-L1 terminal binding Activity assay
The binding activity of the double-antibody molecule (PD-L1 end) to CHO-PD-L1 cells was tested by FCM assay. Preparation of 3% BSA buffer: weighing 4.5g of BSA into 150mL of 1XPBS, uniformly mixing, and placing on ice for later use; antibody dilution: the test antibody and positive control were diluted with 3% BSA to an initial concentration of 800nM, and the subtype control was diluted to an initial concentration of 20. mu.g/mL, at a volume of 300. mu.L, at 10 points in a 3-fold gradient dilution (100+ 200); and (3) detecting the binding activity: cells were counted and plated: counting the R0254-3 cells, and dividing the cells into 96-well V-shaped plates according to 100 mu L and 2E + 05/well; adding 50 mu L of antibody with different concentrations into cells, incubating for 0.5h at 2-8 ℃, adding 50 mu L of ligand, and incubating for 0.5h at 2-8 ℃; centrifuging at 350Xg for 5min, removing supernatant, and adding 200 μ L/well 3% BSA; centrifuging at 350Xg for 5min, removing supernatant, preparing fluorescent antibodies PE Goat anti-human IgG Fc and PE Goat anti-mouse IgG Fc (diluted at 1:500 x) by 3% BSA, adding into a corresponding 96-well plate according to 100 mu L/well, and incubating at 2-8 ℃ for 30 min; centrifuging for 5min at 350g, removing supernatant, and washing cells once with 3% BSA; centrifuging at 350Xg for 5min, removing supernatant, and adding 1XPBS for resuspending cells at 100 μ L/hole; and (4) performing mechanical detection according to the standard operation procedure of the CytoFLEX flow cytometer. The results are shown in FIG. 7, which is comparable in affinity to the molecule without disulfide bond modification (the sequence is the same as that of Complex 2 except for disulfide bond modification), indicating that disulfide bond modification does not affect the affinity of the targeting region.
Example 5 other IL15R alpha molecule disulfide modification
Through verification, the disulfide bond modification position IL15(E90C)/IL15R alpha (P67C) can be successfully applied to the following IL15R alpha structures with different lengths, and the specific sequence is shown in the following table:
Figure BDA0003277908210000061
Figure BDA0003277908210000071
the technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
SEQUENCE LISTING
<110> Guangdong Fengcong pharmaceutical Co Ltd
<120> polypeptide complex of interleukin 15 and its receptor
<130> 2021
<160> 20
<170> PatentIn version 3.5
<210> 1
<211> 546
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 1-1
<400> 1
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Met Ile Arg Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Met Phe
50 55 60
Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Gly Ile His Asp Tyr Gly His Gly Ala Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ile Thr Cys Pro Pro
130 135 140
Pro Met Ser Val Glu His Ala Asp Ile Trp Val Lys Ser Tyr Ser Leu
145 150 155 160
Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly Phe Lys Arg Lys Ala
165 170 175
Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn Lys Ala Thr Asn Val
180 185 190
Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile Arg Asp Cys Ala Leu
195 200 205
Val His Gln Arg Pro Ala Pro Pro Ser Thr Val Thr Thr Ala Gly Val
210 215 220
Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly Lys Glu Pro Ala Ala
225 230 235 240
Ser Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr Thr Ala Ala Ile Val
245 250 255
Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro Ser Thr Gly Thr Thr
260 265 270
Glu Ile Ser Ser His Glu Ser Ser His Gly Thr Pro Ser Gln Thr Thr
275 280 285
Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser His Gln Pro Pro Gly
290 295 300
Val Tyr Pro Gln Gly His Ser Asp Thr Thr Glu Pro Lys Ser Ser Asp
305 310 315 320
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
325 330 335
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
340 345 350
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
355 360 365
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
370 375 380
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
385 390 395 400
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
405 410 415
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
420 425 430
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
435 440 445
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
450 455 460
Thr Cys Arg Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
465 470 475 480
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
485 490 495
Leu Lys Ser Asp Gly Ser Phe Phe Leu Ala Ser Lys Leu Thr Val Asp
500 505 510
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
515 520 525
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
530 535 540
Gly Lys
545
<210> 2
<211> 242
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 1-2
<400> 2
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Val
35 40 45
Tyr Ala Ala Ser His Leu Pro Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile
130 135 140
Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His
145 150 155 160
Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln
165 170 175
Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu
180 185 190
Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val
195 200 205
Thr Glu Ser Gly Cys Lys Glu Cys Glu Cys Leu Glu Glu Lys Asn Ile
210 215 220
Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn
225 230 235 240
Thr Ser
<210> 3
<211> 549
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 2-1
<400> 3
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ile Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Tyr Pro Ser Gly Gly Ile Thr Phe Tyr Ala Asp Thr Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ile Lys Leu Gly Thr Val Thr Thr Val Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ile Thr Cys
130 135 140
Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val Lys Ser Tyr
145 150 155 160
Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly Phe Lys Arg
165 170 175
Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn Lys Ala Thr
180 185 190
Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile Arg Asp Cys
195 200 205
Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val Thr Thr Ala
210 215 220
Gly Val Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly Lys Glu Pro
225 230 235 240
Ala Ala Ser Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr Thr Ala Ala
245 250 255
Ile Val Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro Ser Thr Gly
260 265 270
Thr Thr Glu Ile Ser Ser His Glu Ser Ser His Gly Thr Pro Ser Gln
275 280 285
Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser His Gln Pro
290 295 300
Pro Gly Val Tyr Pro Gln Gly His Ser Asp Thr Thr Glu Pro Arg Gly
305 310 315 320
Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu
325 330 335
Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val
340 345 350
Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val
355 360 365
Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val
370 375 380
Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser
385 390 395 400
Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met
405 410 415
Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala
420 425 430
Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro
435 440 445
Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln
450 455 460
Val Thr Leu Trp Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr
465 470 475 480
Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Asp Asn Thr
485 490 495
Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Asp Leu
500 505 510
Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser
515 520 525
Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser
530 535 540
Arg Thr Pro Gly Lys
545
<210> 4
<211> 245
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 2-2
<400> 4
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Gly
100 105 110
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
115 120 125
Gly Ser Gly Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu
130 135 140
Asp Leu Ile Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser
145 150 155 160
Asp Val His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu
165 170 175
Glu Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp
180 185 190
Thr Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn
195 200 205
Gly Asn Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Cys Leu Glu Glu
210 215 220
Lys Asn Ile Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met
225 230 235 240
Phe Ile Asn Thr Ser
245
<210> 5
<211> 544
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 3-1
<400> 5
Gln Val Gln Leu Glu Ser Glu Gly Gly Leu Phe Lys Pro Thr Asp Thr
1 5 10 15
Leu Thr Leu Thr Cys Thr Val Ser Gly Ser Ser Leu Ser Ser Ser Tyr
20 25 30
Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly
35 40 45
Ile Ile Gly Ser Asn Gly Asn Thr Tyr Tyr Ala Asn Trp Ala Lys Gly
50 55 60
Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Glu Leu Lys Ile Thr
65 70 75 80
Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Gly
85 90 95
Tyr Arg Thr Ser Gly Met Asp Pro Trp Gly Pro Gly Thr Leu Val Thr
100 105 110
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
115 120 125
Gly Ser Gly Gly Gly Gly Ser Gly Ile Thr Cys Pro Pro Pro Met Ser
130 135 140
Val Glu His Ala Asp Ile Trp Val Lys Ser Tyr Ser Leu Tyr Ser Arg
145 150 155 160
Glu Arg Tyr Ile Cys Asn Ser Gly Phe Lys Arg Lys Ala Gly Thr Ser
165 170 175
Ser Leu Thr Glu Cys Val Leu Asn Lys Ala Thr Asn Val Ala His Trp
180 185 190
Thr Thr Pro Ser Leu Lys Cys Ile Arg Asp Pro Ala Leu Val His Gln
195 200 205
Arg Pro Ala Pro Pro Ser Thr Val Thr Thr Ala Gly Val Thr Pro Gln
210 215 220
Pro Glu Ser Leu Ser Pro Ser Gly Lys Glu Pro Ala Ala Ser Ser Pro
225 230 235 240
Ser Ser Asn Asn Thr Ala Ala Thr Thr Ala Ala Ile Val Pro Gly Ser
245 250 255
Gln Leu Met Pro Ser Lys Ser Pro Ser Thr Gly Thr Thr Glu Ile Ser
260 265 270
Ser His Glu Ser Ser His Gly Thr Pro Ser Gln Thr Thr Ala Lys Asn
275 280 285
Trp Glu Leu Thr Ala Ser Ala Ser His Gln Pro Pro Gly Val Tyr Pro
290 295 300
Gln Gly His Ser Asp Thr Thr Glu Pro Arg Gly Pro Thr Ile Lys Pro
305 310 315 320
Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser
325 330 335
Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu
340 345 350
Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro
355 360 365
Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala
370 375 380
Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val
385 390 395 400
Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe
405 410 415
Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr
420 425 430
Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu
435 440 445
Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Trp Cys
450 455 460
Met Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn
465 470 475 480
Asn Gly Lys Thr Glu Leu Asn Tyr Asp Asn Thr Glu Pro Val Leu Asp
485 490 495
Ser Asp Gly Ser Tyr Phe Met Tyr Ser Asp Leu Arg Val Glu Lys Lys
500 505 510
Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly
515 520 525
Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
530 535 540
<210> 6
<211> 245
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 3-2
<400> 6
Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Glu Val Ala Val Gly
1 5 10 15
Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Leu Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Gly Val Glu Ser
65 70 75 80
Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Glu His Ser Val Gly Asn
85 90 95
Val Asp Asn Val Phe Gly Gly Gly Thr Glu Val Val Val Lys Gly Gly
100 105 110
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
115 120 125
Gly Ser Gly Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu
130 135 140
Asp Leu Ile Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser
145 150 155 160
Asp Val His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu
165 170 175
Glu Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp
180 185 190
Thr Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn
195 200 205
Gly Asn Val Thr Glu Ser Gly Cys Lys Cys Cys Glu Glu Leu Glu Glu
210 215 220
Lys Asn Ile Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met
225 230 235 240
Phe Ile Asn Thr Ser
245
<210> 7
<211> 546
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 4-1
<400> 7
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
20 25 30
Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Met Ile Arg Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Met Phe
50 55 60
Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Gly Ile His Asp Tyr Gly His Gly Ala Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ile Thr Cys Pro Pro
130 135 140
Pro Met Ser Val Glu His Ala Asp Ile Trp Val Lys Ser Tyr Ser Leu
145 150 155 160
Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly Phe Lys Cys Lys Ala
165 170 175
Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn Lys Ala Thr Asn Val
180 185 190
Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile Arg Asp Pro Ala Leu
195 200 205
Val His Gln Arg Pro Ala Pro Pro Ser Thr Val Thr Thr Ala Gly Val
210 215 220
Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly Lys Glu Pro Ala Ala
225 230 235 240
Ser Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr Thr Ala Ala Ile Val
245 250 255
Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro Ser Thr Gly Thr Thr
260 265 270
Glu Ile Ser Ser His Glu Ser Ser His Gly Thr Pro Ser Gln Thr Thr
275 280 285
Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser His Gln Pro Pro Gly
290 295 300
Val Tyr Pro Gln Gly His Ser Asp Thr Thr Glu Pro Lys Ser Ser Asp
305 310 315 320
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
325 330 335
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
340 345 350
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
355 360 365
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
370 375 380
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
385 390 395 400
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
405 410 415
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
420 425 430
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
435 440 445
Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu
450 455 460
Thr Cys Arg Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
465 470 475 480
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
485 490 495
Leu Lys Ser Asp Gly Ser Phe Phe Leu Ala Ser Lys Leu Thr Val Asp
500 505 510
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
515 520 525
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
530 535 540
Gly Lys
545
<210> 8
<211> 242
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 4-2
<400> 8
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Val
35 40 45
Tyr Ala Ala Ser His Leu Pro Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser
100 105 110
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile
130 135 140
Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His
145 150 155 160
Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln
165 170 175
Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu
180 185 190
Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val
195 200 205
Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Cys Lys Asn Ile
210 215 220
Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn
225 230 235 240
Thr Ser
<210> 9
<211> 114
<212> PRT
<213> Artificial Sequence
<220>
<223> IL15(E90C)
<400> 9
Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu Ile
1 5 10 15
Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val His
20 25 30
Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu Gln
35 40 45
Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val Glu
50 55 60
Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn Val
65 70 75 80
Thr Glu Ser Gly Cys Lys Glu Cys Glu Cys Leu Glu Glu Lys Asn Ile
85 90 95
Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile Asn
100 105 110
Thr Ser
<210> 10
<211> 175
<212> PRT
<213> Artificial Sequence
<220>
<223> IL15RA-175aa(P67C)
<400> 10
Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val
1 5 10 15
Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly
20 25 30
Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn
35 40 45
Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile
50 55 60
Arg Asp Cys Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val
65 70 75 80
Thr Thr Ala Gly Val Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly
85 90 95
Lys Glu Pro Ala Ala Ser Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr
100 105 110
Thr Ala Ala Ile Val Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro
115 120 125
Ser Thr Gly Thr Thr Glu Ile Ser Ser His Glu Ser Ser His Gly Thr
130 135 140
Pro Ser Gln Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser
145 150 155 160
His Gln Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp Thr Thr
165 170 175
<210> 11
<211> 77
<212> PRT
<213> Artificial Sequence
<220>
<223> IL15RA-77aa(P67C)
<400> 11
Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val
1 5 10 15
Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly
20 25 30
Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn
35 40 45
Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile
50 55 60
Arg Asp Cys Ala Leu Val His Gln Arg Pro Ala Pro Pro
65 70 75
<210> 12
<211> 73
<212> PRT
<213> Artificial Sequence
<220>
<223> IL15RA-73aa(P67C)
<400> 12
Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val
1 5 10 15
Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly
20 25 30
Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn
35 40 45
Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile
50 55 60
Arg Asp Cys Ala Leu Val His Gln Arg
65 70
<210> 13
<211> 86
<212> PRT
<213> Artificial Sequence
<220>
<223> IL15RA-86aa(P67C)
<400> 13
Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val
1 5 10 15
Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly
20 25 30
Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn
35 40 45
Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile
50 55 60
Arg Asp Cys Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val
65 70 75 80
Thr Thr Ala Gly Val Thr
85
<210> 14
<211> 102
<212> PRT
<213> Artificial Sequence
<220>
<223> IL15RA-102aa(P67C)
<400> 14
Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val
1 5 10 15
Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly
20 25 30
Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn
35 40 45
Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile
50 55 60
Arg Asp Cys Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val
65 70 75 80
Thr Thr Ala Gly Val Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly
85 90 95
Lys Glu Pro Ala Ala Ser
100
<210> 15
<211> 449
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 1-3/Complex 4-3
<400> 15
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Asp Ser Ile Thr Ser Gly
20 25 30
Tyr Trp Asn Trp Ile Arg Lys Pro Pro Gly Lys Gly Leu Glu Tyr Ile
35 40 45
Gly Tyr Ile Ser Tyr Thr Gly Ser Thr Tyr Gln Asn Pro Ser Leu Lys
50 55 60
Ser Arg Ile Thr Met Ser Arg Asp Thr Ser Lys Asn Gln Tyr Tyr Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ser Arg Ala Trp Ile Arg Thr Tyr Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Trp
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Asp Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Asp Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys
<210> 16
<211> 215
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 1-4/Complex 4-4
<400> 16
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Val Ser Ser Ser Ile Ser Ser Ser
20 25 30
Asn Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Pro Trp
35 40 45
Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln
65 70 75 80
Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro
85 90 95
Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala
100 105 110
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser
115 120 125
Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu
130 135 140
Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser
145 150 155 160
Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
165 170 175
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
180 185 190
Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys
195 200 205
Ser Phe Asn Arg Gly Glu Cys
210 215
<210> 17
<211> 445
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 2-3
<400> 17
Gln Val Gln Leu Glu Ser Glu Gly Gly Leu Phe Lys Pro Thr Asp Thr
1 5 10 15
Leu Thr Leu Thr Cys Thr Val Ser Gly Ser Ser Leu Ser Ser Ser Tyr
20 25 30
Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly
35 40 45
Ile Ile Gly Ser Asn Gly Asn Thr Tyr Tyr Ala Asn Trp Ala Lys Gly
50 55 60
Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Glu Leu Lys Ile Thr
65 70 75 80
Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Gly
85 90 95
Tyr Arg Thr Ser Gly Met Asp Pro Trp Gly Pro Gly Thr Leu Val Thr
100 105 110
Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro
115 120 125
Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val
130 135 140
Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser
145 150 155 160
Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu
165 170 175
Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp Pro Ser
180 185 190
Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val
195 200 205
Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro
210 215 220
Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile
225 230 235 240
Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile
245 250 255
Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln
260 265 270
Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln
275 280 285
Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu
290 295 300
Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys
305 310 315 320
Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys
325 330 335
Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro
340 345 350
Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Arg Val Thr
355 360 365
Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys
370 375 380
Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Lys Ser Asp Gly
385 390 395 400
Ser Tyr Phe Met Ala Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val
405 410 415
Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn
420 425 430
His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
435 440 445
<210> 18
<211> 217
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 2-4
<400> 18
Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Glu Val Ala Val Gly
1 5 10 15
Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Leu Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Gly Val Glu Ser
65 70 75 80
Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Glu His Ser Val Gly Asn
85 90 95
Val Asp Asn Val Phe Gly Gly Gly Thr Glu Val Val Val Lys Arg Thr
100 105 110
Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu
115 120 125
Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro
130 135 140
Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn
145 150 155 160
Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr
165 170 175
Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His
180 185 190
Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile
195 200 205
Val Lys Ser Phe Asn Arg Asn Glu Cys
210 215
<210> 19
<211> 450
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 3-3
<400> 19
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ile Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Tyr Pro Ser Gly Gly Ile Thr Phe Tyr Ala Asp Thr Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ile Lys Leu Gly Thr Val Thr Thr Val Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val
115 120 125
Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr
130 135 140
Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr
145 150 155 160
Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser
180 185 190
Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala
195 200 205
Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile
210 215 220
Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile
245 250 255
Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp Val Ser Glu Asp
260 265 270
Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His
275 280 285
Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg
290 295 300
Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys
305 310 315 320
Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ala Pro Ile Glu
325 330 335
Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala Pro Gln Val Tyr
340 345 350
Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys Gln Val Thr Leu
355 360 365
Thr Cys Arg Val Thr Asp Phe Met Pro Glu Asp Ile Tyr Val Glu Trp
370 375 380
Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val
385 390 395 400
Leu Lys Ser Asp Gly Ser Tyr Phe Met Ala Ser Lys Leu Arg Val Glu
405 410 415
Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His
420 425 430
Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro
435 440 445
Gly Lys
450
<210> 20
<211> 217
<212> PRT
<213> Artificial Sequence
<220>
<223> Complex 3-4
<400> 20
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
85 90 95
Ser Thr Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Arg Thr
100 105 110
Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu
115 120 125
Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro
130 135 140
Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn
145 150 155 160
Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr
165 170 175
Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His
180 185 190
Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile
195 200 205
Val Lys Ser Phe Asn Arg Asn Glu Cys
210 215

Claims (10)

1. An IL15/IL15R alpha polypeptide complex, wherein a non-natural interchain bond is formed between IL15 and IL15R alpha, the non-natural interchain bond is formed between a first mutant residue of IL15 and a second mutant residue of IL15R alpha, the first mutant residue of IL15 is an E mutation at position 90 to C, and the second mutant residue of IL15R alpha is a P mutation at position 67 to C.
2. The IL15/IL15R a polypeptide complex of claim 1, the IL15R a extracellular region full length or IL15R a sushi domain.
3. The IL15/IL15R a polypeptide complex of claim 2, the IL15R a having 73-175 amino acids.
4. The IL15/IL15R a polypeptide complex according to claim 1, the IL15 having the amino acid sequence shown in SEQ ID No. 9.
5. The IL15/IL15R a polypeptide complex of claim 1, the IL15R a having the amino acid sequence set forth in SEQ ID No.10, SEQ ID No.11, SEQ ID No.12, SEQ ID No.13, or SEQ ID No. 14.
6. An isolated nucleic acid encoding the IL15/IL15R alpha polypeptide complex of any one of claims 1 to 5.
7. A vector comprising the nucleic acid of claim 6.
8. A host cell comprising the nucleic acid of claim 4 or the vector of claim 7.
9. A pharmaceutical composition comprising the IL15/IL15R a polypeptide complex of any one of claims 1-5, and a pharmaceutically acceptable carrier, excipient, or stabilizer.
10. Use of the IL15/IL15R alpha polypeptide complex of any one of claims 1 to 5 in the manufacture of a medicament for the treatment of a disease.
CN202111123534.XA 2021-09-24 2021-09-24 Interleukin 15 and polypeptide complex of receptor thereof Active CN113943374B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202111123534.XA CN113943374B (en) 2021-09-24 2021-09-24 Interleukin 15 and polypeptide complex of receptor thereof
TW111136248A TW202321315A (en) 2021-09-24 2022-09-23 Polypeptide complex of interleukin 15 and interleukin 15 receptor
PCT/CN2022/121068 WO2023046116A1 (en) 2021-09-24 2022-09-23 Polypeptide complex of interleukin 15 and receptor thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111123534.XA CN113943374B (en) 2021-09-24 2021-09-24 Interleukin 15 and polypeptide complex of receptor thereof

Publications (2)

Publication Number Publication Date
CN113943374A true CN113943374A (en) 2022-01-18
CN113943374B CN113943374B (en) 2024-04-30

Family

ID=79328538

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111123534.XA Active CN113943374B (en) 2021-09-24 2021-09-24 Interleukin 15 and polypeptide complex of receptor thereof

Country Status (1)

Country Link
CN (1) CN113943374B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023046116A1 (en) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 Polypeptide complex of interleukin 15 and receptor thereof
WO2023138573A1 (en) * 2022-01-21 2023-07-27 广东菲鹏制药股份有限公司 Complex of interleukin 21 and receptor thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499725A (en) * 2010-06-08 2020-08-07 皮里斯制药有限公司 Tear lipocalin muteins binding to the I L-4 receptor α

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499725A (en) * 2010-06-08 2020-08-07 皮里斯制药有限公司 Tear lipocalin muteins binding to the I L-4 receptor α

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023046116A1 (en) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 Polypeptide complex of interleukin 15 and receptor thereof
WO2023138573A1 (en) * 2022-01-21 2023-07-27 广东菲鹏制药股份有限公司 Complex of interleukin 21 and receptor thereof

Also Published As

Publication number Publication date
CN113943374B (en) 2024-04-30

Similar Documents

Publication Publication Date Title
JP6918405B2 (en) A method of increasing the level of secretion of interleukin 2 and proteins derived from it.
CN110840830B (en) Injection preparation of anti-CT L A-4 monoclonal antibody
CN114621345B (en) anti-LAG-3 monoclonal antibody, antigen binding fragment thereof and application thereof
JP2013521258A (en) Selective antibody enhancement
CN113943374A (en) Polypeptide compound of interleukin 15 and receptor thereof
CN110655579B (en) Novel anti-CT L A-4 monoclonal antibody and application thereof
CN109867725B (en) PD-1-Fc fusion protein and preparation method and application thereof
CN112618698B (en) Injection preparation of human interleukin 10-Fc fusion protein
CN112625137B (en) Human interleukin 10-Fc fusion protein and medical application thereof
CN114276445B (en) Rotavirus recombinant protein specific antibody, plasmid vector and method
CN113667004A (en) Interleukin 2 mutant
CN115819580B (en) High-affinity rabbit monoclonal antibody aiming at human IL-12 and application thereof
CN112679615B (en) Fusion protein
CN113308491B (en) Recombinant plasmid and recombinant cell for co-expressing NFAT and human DNAM-1 protein, and construction method and application thereof
CN113234152B (en) Programmed death receptor-ligand 1 (PD-L1) specific binding polypeptide and application thereof
CN112501192B (en) Hybridoma cell strain for generating anti-human IL21 monoclonal antibody and application thereof
CN115260296A (en) Polypeptide based on specificity of autoimmune disease, specific antibody and application
WO2023138573A1 (en) Complex of interleukin 21 and receptor thereof
CN110872356B (en) Bispecific antibodies and methods of use thereof
CN118546233B (en) Interleukin-21 mutant and application thereof
CN112442496A (en) Arginine deiminase mutant and application thereof
CN112480247B (en) Anti-human serum albumin monoclonal antibodies
CN113999306B (en) Method for obtaining antibody for recognizing space conformation epitope
CN118852386A (en) A peptide derived from MAGE A4 and complexes thereof
CN116253793A (en) Nanometer antibody and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40067519

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant